Cargando…

Predicting Factors for Refractory Kawasaki Disease

BACKGROUND AND OBJECTIVES: About 10-15% of Kawasaki disease (KD) is refractory to intravenous immunoglobulin (IVIG) therapy. This study was designed to investigate the predicting factors for refractory KD. SUBJECTS AND METHODS: We reviewed retrospectively the clinical records of 77 patients with typ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Do, Young-Sun, Kim, Ki-Won, Chun, Jin-Kyong, Cha, Byung Ho, Namgoong, Mee Kyung, Lee, Hae Yong
Formato:	Texto
Lenguaje:	English
Publicado:	The Korean Society of Cardiology 2010
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2877789/ https://www.ncbi.nlm.nih.gov/pubmed/20514335 http://dx.doi.org/10.4070/kcj.2010.40.5.239

Ejemplares similares

Relationship Between Gallbladder Distension and Lipid Profiles in Kawasaki Disease
por: Kim, Ki-Won, et al.
Publicado: (2010)

Elevated Serum Levels of IL-21 in Kawasaki Disease
por: Bae, Yon Jung, et al.
Publicado: (2012)

Interleukin-21 Receptor Gene Polymorphisms in Kawasaki Disease
por: Kim, Mi Hyun, et al.
Publicado: (2013)

Infliximab Treatment for Refractory Kawasaki Disease in Korean Children
por: Song, Min Seob, et al.
Publicado: (2010)

Recurrent refractory Kawasaki disease
por: Costa Reis, P, et al.
Publicado: (2011)

Clinical characteristics of hemophagocytic lymphohistiocytosis following Kawasaki disease: differentiation from recurrent Kawasaki disease
por: Kang, Hae-Ryong, et al.
Publicado: (2013)

Polymorphisms of methylenetetrahydrofolate reductase are not a risk factor for Kawasaki disease in the Korean population
por: Yoon, Kyung Lim, et al.
Publicado: (2011)

Prediction of Resistance to Standard Intravenous Immunoglobulin Therapy in Kawasaki Disease
por: Lee, Sang Min, et al.
Publicado: (2014)

Low-dose Methotrexate Therapy for Intravenous Immunoglobulin-resistant Kawasaki Disease
por: Lee, Taek Jin, et al.
Publicado: (2008)

Prediction of unresponsiveness to second intravenous immunoglobulin treatment in patients with Kawasaki disease refractory to initial treatment
por: Seo, Euri, et al.
Publicado: (2016)

High antistreptolysin O titer is associated with coronary artery lesions in patients with Kawasaki disease
por: Min, Dong Eun, et al.
Publicado: (2019)

Transforming growth factor beta receptor II polymorphisms are associated with Kawasaki disease
por: Choi, Yu Mi, et al.
Publicado: (2012)

Mycoplasma pneumoniae infection in patients with Kawasaki disease
por: Lee, Mi Na, et al.
Publicado: (2011)

Spontaneous defervescence and its prediction in the acute phase of Kawasaki disease
por: Shin, Eun Jung, et al.
Publicado: (2022)

Infliximab as rescue therapy in refractory Kawasaki disease
por: Rodríguez-González, Moisés, et al.
Publicado: (2014)

Refractory Kawasaki disease: diagnostic and management challenges
por: Duignan, Sophie, et al.
Publicado: (2019)

Cyclosporine for refractory Kawasaki disease with psoriasiform eruption
por: Leyendecker, Mara, et al.
Publicado: (2021)

Refractory Kawasaki Disease—a Challenge for the Pediatrician
por: Abraham, Deepu, et al.
Publicado: (2021)

Clinical outcome of patients with refractory Kawasaki disease based on treatment modalities
por: Kim, Hyun Jung, et al.
Publicado: (2016)

Clinical characteristics of Kawasaki disease with sterile pyuria
por: Choi, Ja Yun, et al.
Publicado: (2013)

Risk factors for refractory Kawasaki disease: clinical records of the paediatric clinic of palermo
por: Maggio, Maria Cristina, et al.
Publicado: (2014)

Multicenter, Single-Arm, Phase IV Study of Combined Aspirin and High-Dose “IVIG-SN” Therapy for Pediatric Patients with Kawasaki Disease
por: Yoon, Kyung Lim, et al.
Publicado: (2017)

Risk Factors for Failure of Initial Intravenous Immunoglobulin Treatment in Kawasaki Disease
por: Cha, Sungho, et al.
Publicado: (2008)

Mycoplasma Infection as a cause of Persistent Fever after Intravenous Immunoglobulin Treatment of Patients with Kawasaki Disease: Frequency and Clinical Impact
por: Park, Hye Rim, et al.
Publicado: (2017)

Consortium-Based Genetic Studies of Kawasaki Disease in Korea: Korean Kawasaki Disease Genetics Consortium
por: Lee, Jong-Keuk, et al.
Publicado: (2015)

Elevated Plasma Apurinic/Apyrimidinic Endonuclease 1/Redox Effector Factor-1 Levels in Refractory Kawasaki Disease
por: Lee, Yu-Ran, et al.
Publicado: (2022)

Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study
por: Ulambayar, Bastsetseg, et al.
Publicado: (2019)

Meta-analysis of factors predicting resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease
por: Baek, Jin-Young, et al.
Publicado: (2016)

Non-Responders to Intravenous Immunoglobulin and Coronary Artery Dilatation in Kawasaki Disease: Predictive Parameters in Korean Children
por: Kim, Bo Young, et al.
Publicado: (2016)

Severe refractory Kawasaki disease in seven infants in the COVID-19 era
por: Vergnano, Stefania, et al.
Publicado: (2020)

Cyclophosphamide use in treatment of refractory Kawasaki disease with coronary artery aneurysms
por: Halyabar, Olha, et al.
Publicado: (2021)

Factors Predicting Resistance to Intravenous Immunoglobulin and Coronary Complications in Kawasaki Disease: IVIG Resistance in Kawasaki Disease
por: Han, Ji Whan
Publicado: (2017)

First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients
por: Kim, Seung Tae, et al.
Publicado: (2020)

Differentiation between incomplete Kawasaki disease and secondary hemophagocytic lymphohistiocytosis following Kawasaki disease using N-terminal pro-brain natriuretic peptide
por: Choi, Jung Eun, et al.
Publicado: (2018)

Predictive factors of resistance to intravenous immunoglobulin and coronary artery lesions in Kawasaki disease
por: Lee, Hye Young, et al.
Publicado: (2016)

Under-Recognized Macrophage Activation Syndrome in Refractory Kawasaki Disease: A Wolf in Sheep’s Clothing
por: Rhee, Sangwon, et al.
Publicado: (2022)

Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma
por: Cho, Hee Jeong, et al.
Publicado: (2023)

Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma
por: Cho, Hee Jeong, et al.
Publicado: (2023)

Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease
por: Chan, Han, et al.
Publicado: (2019)

Infliximab as a rescue therapy in the management of refractory typical infantile Kawasaki disease
por: Venkatnarayanan, K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jtr5lohb46vtpvcretn3qvffsm